Publications

49. Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation.
Sakamoto KM, Kim K, Verma R, Ransick A, Stein B, Crews CM, Deshaies RJ
Mol Cell Proteomics 2003 2(12):1350-1358
48. Feeding the Machine: Mechanisms of Proteasome-catalyzed Degradation of Ubiquinated Proteins.
Crews CM
Curr Opin in Chemical Biology 2003 7(5):534-539
47. Chemical genetics: adding to the developmental biology toolbox.
Yeh JR, Crews CM
Developmental Cell 2003 5(1):11-19
46. Simplified synthetic TMC-95A/B analogues retain the potency of proteasome inhibitory activity.
Yang ZQ, Kwok BH, Lin S, Koldobskiy MA, Crews CM, Danishefsky SJ
ChemBioChem 2003 4(6):508-513
45. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro.
Garrett IR, Chen D, Gutierrez G, Zhao M, Excobedo A, Rossini G, Harris SE, Gallwitz W, Kim KB, Hu S, Crews CM, Munch GR
J. Clin Invest. 2003 111(11):1771-1782
44. Small-molecule inhibitors of the cell cycle: an overview.
Crews CM, Shotwell JB
Progress in Cell Cycle Research 2003 5():125-133
43. Natural and Synthetic Inhibitors of the Proteasome. Proteasome Inhibitors in Cancer Therapy.
Crews CM, Kim KB
J. Adams, Editor 2003 ():
42. Chemical genetics: a small molecule approach to neurobiology.
Koh B, Crews CM
Chemical Genetics: A Small Molecule Approach to Neurobiology Neuron 2002 36(4):563-566
41. Total synthesis of luminacin D.
Shotwell JB, Krygowski ES, Hines J, Koh B, Huntsman EWD, Choi HW, Schneekloth JS Jr., Wood JL, Crews CM
Organic Letters 2002 4(18):3087-3089
40. Inhibitors of NF-ĸB Signalling: Design and Synthesis of a Biotinylated Isopanepoxydone Affinity Reagent.
Shotwell JB, Koh B, Ndubuisi M, Choi HW, Medina E, Wood JL, Crews CM
Bioorganic and Medicinal Chemistry Letters 2002 12(23):3463-3466
39. Characterization of a novel mammalian phosphatase having sequence similarity to Schizosaccharomyces pombe PHO2 and Saccharomyces cerevisiae PHO13.
Ndubuisi M, Kwok B, Vervoort J, Elofsson M, Crews CM
Biochemistry 2002 41(24):7841-7848
38. Protacs: Chimeric Molecules that Target Proteins to the skp1-Cullin-F box complex for Ubiquitination and Degradation.
Sakamoto KM, Kim KB, Kumagai A, Mercurio F, Crews CM, Deshaies RJ
Proc. Natl. Acad. Sci. USA 2001 98(15):8554-8559
37. The Anti-inflammatory Natural Product Parthenolide from the Medicinal Herb Feverfew Directly Binds to and Inhibits IkappaB Kinase.
Kwok HB, Koh B, Ndubuisi M, Elofsson M, Crews CM
Chemistry & Biology 2001 8(8):759-766
36. The Ubiquitin-proteasome Pathway and Proteasome Inhibitors.
Myung J, Kim K, Crews CM
Medicinal Research Reviews 2001 21(4):245-273
35. Lack of Proteasome Active Site Allostery as Revealed by Subunit-Specific Inhibitors.
Myung J, Kim K, Lindsten KK, Dantuma NP, Crews CM
Molecular Cell 2001 7(2):411-420
34. Cells adapted to the proteasome inhibitor 4-hydroxy- 5-iodo-3-nitrophenylacetyl-Leu-Leu-leucinal-vinyl sulfone require enzymatically active proteasomes for continued survival.
Princiotta MF, Schubert U, Bacik I, Bennink JR, Myung J, Crews CM, Yewdell JW
Proc. Natl. Acad. Sci. USA 2001 98(2):513-518
33. The Antiangiogenic Agent TNP-470 requires p53 and p21 CIP/WAF for Endothelial Cell Growth Arrest.
Yeh J, Mohan R, Crews CM
Proc. Natl. Acad. Sci. USA 2000 97(23):12782-12787
32. Efficient steroselective synthesis of isopanepoxydone and panepoxydone: A re-assignment of relative steriochemistry.
Shotwell JB, Hu S, Medina E, Abe M, Cole R, Crews CM, Wood JL
Tetrahetron Letters 2000 41():9639-9643
31. The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses.
Schwarz K, de Giuli R, Schmidtke G, Kostka S, van den Broek M, Kim K, Crews CM
J. Immunology 2000 164(12):6147-6157
30. Small-Molecule inhibitors of the Cell Cycle.
Crews CM, Mohan R
Curr. Opin. Chem. Biol. 2000 4(1):47-53

Pages